Health Systems Development
DRUG MANAGEMENT PRIORITY ISSUES 1. 2. 3. 4.
Potential cost benefit of joint procurement not realized. ol. Fe w countries ha te ca pacity ffor or dr ug rree gistr a tion and quality contr control. havv e adequa adequate capacity Inadequa te dr ug mana or ma tion. Inadequate managg ement inf infor mation. Inadequa te consumer pr otection aagg ainst ina ppr opria te dr ug ad actices Inadequate protection inappr ppropria opriate advv er tising pr practices actices..
OBJECTIVE 1 Ef ficient and ef hanisms ffor or joint pr ocur ement, r e gistr a tion and utiliza tion of dr ugs Efficient efff ecti ectivv e mec mechanisms procur ocurement, utilization established.
INDICA INDICATT ORS 1.1 Number of countries (a) participating in a joint procurement initiative and (b) implementing policies for generic drugs increased by end 2003. 1.2 All countries will have updated legislation or policies and supportive laboratory facilities for effective monitoring of drugs to be registered and/or in use by end 2003.
OBJECTIVE 2 Systems ffor or aappr ppr opria te dr ug utiliza tion impr ppropria opriate utilization improo v ed.
INDICA INDICATT ORS 2.1 All countries will have mechanisms for at least annual updated national formularies and/or Essential Drug lists by end 2000. 2.2 All countries will have initiated the conduct of annual drug utilization reviews by end 2003.
OBJECTIVE 3 Ca pacity ffor or incr easing consumer aaw w ar eness of risks in the ina ppr opria te use of dr ugs (conCapacity increasing areness inappr ppropria opriate titivv e ther eased. v entional and alter na nati theraa pies) incr increased.
INDICA INDICATTOR 3.1 All countries will have client advocacy and educational programmes (hot lines, poison centres) for appropriate use of drugs and health promoting products by end 2003.
33